S121: REDUCED RATE OF VASO-OCCLUSIVE CRISES (VOCS) IN PATIENTS (PTS) WITH SICKLE CELL DISEASE (SCD) TREATED WITH CRIZANLIZUMAB FOR 12 MONTHS: RESULTS FROM A REAL-WORLD, MANAGED ACCESS PROGRAM (MAP)

• A Silva-Pinto,
• R Colombatti,
• A Pasanisi,
• F Arcioni,
• L DeBonnett,
• W Soliman,
• R Sarkar,
• R Cançado

Affiliations

A Silva-Pinto

1 Regional Blood Center, Department of Medical Imaging, Ribeirão Preto School of Medicine, São Paulo, BRAZIL

R Colombatti

2 Azienda Ospedale-Università di Padova, Padova, ITALY

A Pasanisi

3 Ospedale ‘A. Perrino’, Brindisi, ITALY

F Arcioni

4 Pediatric Hematology and Oncology with Bone Marrow Transplantation, Azienda Ospedaliera di Perugia, Perugia, ITALY

L DeBonnett

5 Novartis Pharmaceuticals Corporation, East Hanover, UNITED STATES

W Soliman

6 Novartis Saudi Ltd, Riyadh, SAUDI ARABIA

R Sarkar

7 Novartis Corporation (Malaysia) Sdn. Bhd, Selangor, MALAYSIA

R Cançado

8 Department of Hematology and Oncology, Santa Casa de São Paulo School of Medicine, São Paulo, BRAZIL